【摘要】 目的:研究对于非小细胞型肺癌晚期患者使用克唑替尼治疗的临床疗效。方法:回顾性分析2015年1月～2019年1月我院使用克唑替尼靶向治疗非小细胞型肺癌患者晚期共64例(以下简称克唑替尼组),同时另选使用标准化疗方案(多西他赛+顺铂)的晚期非小细胞型肺癌64例作为对照组(以下简称DP组),相对比以上不同两组肿瘤患者的反应疗效指标(包括CR、PR、SD、PD、ORR、DCR)、化疗所产生的毒副反应(包括有白细胞相对减少、血小板也相对减少、贫血、以及胃肠道不良反应、肝功能产生障碍、和皮疹)、生存分析指标(PFS、OS)。结果:两组的肿瘤疗效指标CR,PR,SD,PD,ORR,DCR均无统计学差异。两组患者的化疗毒副反应无显著差异。克唑替尼组的PFS显著长于DP组;克唑替尼组的OS显著长于DP组。结论:克唑替尼的肿瘤反应与DP标准化疗方案疗效相当,且毒副反应未增加,但可以显著增加患者PFS和OS。目前临床上,对于治疗非小细胞型肺癌的值得有效推广的方法是克唑替尼靶向治疗。更多还原

【Abstract】 Objectives To study the clinical effects of Crizotinib therapy in patients of advanced non-small cell lung cnacer.Methods A retrospective analysis of 64 non-small-cell lung cancer patients (hereinafter referred to as the crizotinib group) who admitted to our department from January 2015 to January 2019 were selected,which contrast with 64 patients treated by DP chemotherapy.To obeserve the clinical effects of tumor (CR,PR,SD,PD,ORR,DCR) and the side effects of chemitherapy (leukopenia,thrombocytopenia,anemia,gastrointestinal reaction,liver dysfunction,rash),suivival analysis (PFS,OS).Results The CR,PR,SD,PD,ORR,DCR have no significant difference,the side effects of chemitherapy have no significant difference,but the PFS and OS of CTET is longer than ET.Conclusion The tumor response of crizotinib is equivalent to that of DP standard chemotherapy,and the side effects are not increased,but it can significantly increase the PFS and OS of patients.Crizotinib is a effective way to treat non-small cell lung cancer,it is worth to spread to clinical application.更多还原